ExCEEd Orphan s.r.o. announces cooperation with myTomorrows for selected Central and Eastern European countries

ExCEEd Orphan s.r.o., a company providing full range of market entry services, has entered an agreement for cooperation in 6 countries in Central and Eastern Europe (Czech Republic, Hungary, Romania, Serbia, Slovakia and Slovenia) with myTomorrows. According to this agreement, ExCEEd Orphan shall provide myTomorrows reimbursement consultancy services in the above mentioned 6 countries, with the aim of securing reimbursement from local governments or health insurance funds for the treatment of already identified patients suffering from Duchenne Muscular Dystrophy (DMD) with innovative targeted treatments recently approved by FDA.

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan comments: “We at ExCEEd Orphan are really pleased to assist myTomorrows in their efforts to bring first targeted treatments for DMD patients in need in our countries. We are looking forward continuing our mission of accelerating access to such innovative therapies.”

ExCEEd Orphan was founded in 2018 by 5 rare disease experts from multiple CEE countries. The company is focusing on break-through treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEEd Orphan includes products in therapeutic areas like hematology, neurology, immunology, and metabolic diseases.

For further information, please refer to www.exceedorphan.com

Get in touch

With real experts in CEE region.

Send us an e-mail